REG - Feedback PLC - Notice of Results & Retail Investor Presentation

FeedbackAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250908:nRSH2410Ya&default-theme=true

RNS Number : 2410Y  Feedback PLC  08 September 2025

 

Feedback plc

 

Notice of Results & Retail Investor Presentation

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical
infrastructure specialist, expects to announce results for the 12 months ended
31 May 2025 (the "Period") on Wednesday 17 September 2025.

 

Investor Presentation: 16:00, Wednesday 17 September

Management will be providing a presentation and hosting an investor Q&A
session on the Company's results and future prospects on Wednesday 17
September at 16:00. Investors can sign up for free and register to meet FDBK
via the following link:
https://www.investormeetcompany.com/feedback-plc/register-investor
(https://www.investormeetcompany.com/feedback-plc/register-investor)

Investors who have already registered on the Investor Meet Company platform to
meet the Company will automatically be invited.

--Ends--

Enquiries:

 

 Feedback plc                                 +44 (0) 20 3997 7634

 Tom Oakley, CEO                              IR@fbk.com (mailto:IR@fbk.com)

 Anesh Patel, CFO

 Panmure Liberum Limited (NOMAD and Broker)   +44 (0)20 7886 2500

 Emma Earl/ Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Walbrook PR Ltd;                             Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                              (mailto:feedbackplc@walbrookpr.com)
 Nick Rome/Joe Walker                         07748 325 236 or 07407 020 470

 

 

About Feedback plc

 

Feedback plc liberates the data and knowledge from multiple healthcare IT
systems and delivers better workflow to enable clinicians to communicate,
collaborate and provide the best healthcare for their patients. We connect
care settings with diagnostic and other relevant data to drive better, faster,
safer decision that improve outcomes for patients.

 

By linking different clinical systems together into a seamless view of the
patient, we can streamline patient pathways and deliver a digital health and
diagnostics record across multiple care providers.

 

Bleepa® is our communication and collaboration platform that displays
clinical results at a certified and regulated quality, which enables
multi-disciplinary team working and diagnostic-enhanced advice and guidance.
CareLocker® is our patient-facing platform that gives patients access and
control over their diagnostic and other clinical data.

 

The Company has a number of growth opportunities domestically and
internationally across a range of public and private healthcare markets
including the NHS. Our highly scalable software-as-a-service (SaaS) based
model is expected to provide increasing levels of revenue visibility as the
Company grows its customer base.

 

https://feedbackmedical.com/
(https://urldefense.proofpoint.com/v2/url?u=https-3A__feedbackmedical.com_&d=DwMGaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=lwwmT1lSfgELFLcwvlJQ2ZXDKcVbkQyitKwD17cChBQ&m=oBFM-ht-5vvdSXufzCuQmLfPWIaMcFGcjFY8Tl7Z-dsq0iW8FbXgExGw9gLP3va-&s=kayb21_5OhwDnHa1pJnJQjB1999VQgQynAFl7rWXro4&e=)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORLAMMTMTTMBLA